SOURCE: Skystar Bio-Pharmaceuticals

Skystar Bio-Pharmaceuticals

October 27, 2015 09:01 ET

Skystar Bio-Pharmaceutical Company Receives Approval for T-Factor Animal Supplement Patent From PRC's Patent Office

XI'AN, CHINA--(Marketwired - Oct 27, 2015) - Skystar Bio-Pharmaceutical Company (NASDAQ: SKBI) (the "Company"), a China-based manufacturer and distributor of veterinary medicine, vaccines, micro-organisms and feed additives, announced receiving new patent, number ZL201310259528.6, from the State Intellectual Property Office of the PRC (SIPO), on August 12, 2015. The Company originally filed the patent, which is named "Multi-joint-specific transfer factor and preparation methods," in 2013. The patent relates to a process for intended use in the animal pharmaceutical space to improve the way specific transfer factor (T-factors) are cultivated for large scale production purposes.

T-factors are widely accepted and used around the world as animal health supplements, administered orally, to support immune systems and to prevent diseases in poultry and livestock, including: porcine circovirus, porcine reproductive and respiratory syndrome, pseudorabies, swine mycoplasma pneumonia, swine fever, avian flu, Newcastle disease, avian infectious bronchitis, duck plague, and mycoplasma gallisepticum disease. The patent is valid for 20 years.

T-factors support the overall balance and health of an animal's immune system by positively stimulating an animal's immune system and response to pathogens. Skystar's patented process for the preparation and cultivation of T-factor was developed at Skystar's Huxian research and development facility. The traditional process for cultivating T-factor occurs by freezing and thawing materials, followed by membrane dialysis. The main disadvantage of the traditional method of harvesting T-factor is low yield relative to extraction time. Skystar's newly patented process for harvesting T-factors uses a harvesting method that replaces traditional membrane dialysis and filtration with centrifugation, microfiltration and ultrafiltration to extract the T-factor, thus greatly shortening the production cycle, saving manpower, and increasing T-factor yield to industrial production levels.

Mr. Weibing Lu commented, "Skystar is pleased to have final approval for this patent, which was developed at our labs in Huxian. The Company believes that the work performed at Skystar's research and development laboratories and sets a new bar for product development in the animal health space and we look forward to developing and launching these efforts into our product portfolio."

The Company is currently working on the commercial application and development of its patented T-factor production process.

About Skystar Bio-Pharmaceutical Company

Skystar is a China-based developer, manufacturer and distributor of veterinary healthcare and medical care products. Skystar has four product lines: veterinary medicines, probiotics, vaccines and feed additives formulated and packaged in house across several modern manufacturing and distributions facilities. Skystar's distribution network includes almost 3,000 distribution agents of which 360 are franchised stores with exclusivity agreements covering 29 provinces throughout China. For additional information, please visit http://www.skystarbio-pharmaceutical.com.

Safe Harbor Statements

When used in this release, the words "intends," "believes," "anticipated," and "expects," and similar expressions are intended to identify forward-looking statements. Forward-looking statements include, without limitation, the Company's ability to complete its IgG kit effort as well as other related efforts at the Huxian facilities, the Company's ability to timely, effectively and accurately assess the efficacy and commercial potential of any technologies that may results from such R&D efforts, the Company's ability to timely and effectively commercialize any such technologies. The Company undertakes no obligation to publicly release the result of any revision to these forward-looking statements which may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

Contact Information

  • Contact:
    Skystar Bio-Pharmaceutical Company
    Scott Cramer
    Director - Corporate Development & U.S. Representative
    (407) 645-4433